allogeneic cell therapies

Natural killer cells
#allogeneic cell therapies #Cancer immunotherapy #Cancer research #Cancer treatment

Zelluna Immunotherapy secures funding for cancer treatments

Investment from Takeda ventures will fund the development of Zelluna Immunotherapy’s allogeneic T Cell Receptor Natural Killer (TCR-NK) cells for the treatment of cancer. The funds will enable the advancement of a lead TCR-NK product through manufacturing to Clinical Trial Application (CTA) / Investigational New Drug Application (IND) readiness and,… Read More

#Business & Investment #Cancer Research #News